Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Omixon logo — Our mission: enabling histocompatibility labs to turn the be...

Omixon

Our mission: enabling histocompatibility labs to turn the benefits of innovative techs into better transplant outcomes

Founded 2011 Hungary Hungary 58 employees Series C Biotechnology

General Information

Company Name Omixon
Founded Year 2011
Location Hungary Hungary
Employees 58
Industries Biotechnology
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Omixon. To contact Omixon, visit omixon.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Omixon compare?

A PDF of Omixon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Omixon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Omixon

Omixon, founded in 2011 and headquartered in Hungary, is a prominent player in the biotechnology industry. The company's mission, as outlined in their slogan, is to enable histocompatibility labs to harness the benefits of innovative technologies for improved transplant outcomes. Omixon's global presence spans across the United States, Brazil, and the Netherlands, extending its reach to more than 100 laboratories worldwide. Known for its multidisciplinary expertise in bioinformatics, software engineering, molecular biology, and regulatory science, Omixon has been instrumental in translating molecular biology innovations into cutting-edge products for transplant diagnostics. The company achieved a significant milestone in 2014 by becoming the first to successfully introduce NGS-based HLA typing kit and software with the launch of Holotype HLA and HLA Twin. These products are revered for delivering highly accurate high-resolution HLA genotyping and are extensively utilized in 100+ laboratories worldwide. Omixon continued its trailblazing efforts with the release of the NanoTYPE HLA™, a high-resolution HLA genotyping product offering a remarkable turnaround time of less than 5 hours on the Oxford Nanopore sequencing platform, complemented by the NanoTYPER™ analysis software. Furthermore, the company made waves in the industry with the introduction of the groundbreaking HoloGRAFT, the first donor-derived cell-free DNA kit designed for laboratories and featuring donor-informative genetic markers. Primed for strategic growth, Omixon attracted a Series C investment on 05 January 2017, led by Marton Szoke and FastVentures. Stepping into a new chapter, Omixon's acquisition by Werfen was finalized in Barcelona, Spain, on October 16, 2024, following the attainment of all requisite regulatory and antitrust approvals. This acquisition marks a pivotal moment in Omixon's trajectory, positioning the company for potential advancements and expanded opportunities within the biotechnology landscape.

Business keywords: Transplant diagnostics, HLA genotyping, Molecular biology, Bioinformatics, NGS-based technology, Regulatory science, Histocompatibility laboratories, Innovative technologies, Global operations, Software engineering, High-resolution genotyping, Oxford Nanopore sequencing, Cell-free DNA analysis, Donor-informative genetic markers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C Undisclosed 2
Marton Szoke, FastVentures
05 Jan 2017
Series B Undisclosed 2
FastVentures, Marton Szoke
01 Feb 2015
Series A Undisclosed 2
Marton Szoke, FastVentures
30 May 2012
Series A Undisclosed 1
Euroventures
Euroventures
12 Mar 2012

Omixon Alternatives & Competitors

View All Alternatives
Omixon vs
CareDx, Inc.
CareDx, Inc. United States

Creating life-changing solutions that enable transplant patients to thrive.

Post-IPO Equity
812 employees
Biotechnology, Health Care
Omixon vs
GeneCast Biotechnology Co., Ltd.
GeneCast Biotechnology Co., Ltd. China

Founded in November, 2014, Genecast (Beijing) Biotechnology Co. is located in HealthWork (Beijing) I...

Series E
21 employees
Biotechnology, Health Care
Omixon vs
BMR Genomics
BMR Genomics Italy

Empowering Research, Enhancing Lives Through Genomics.

20 employees
Biotechnology, Health Care
View all alternatives

FAQ About Omixon

Our mission: enabling histocompatibility labs to turn the benefits of innovative techs into better transplant outcomes
Omixon was founded in 2011.
Omixon is headquartered in Hungary.
Omixon operates in Biotechnology. Its work centres on Transplant diagnostics, HLA genotyping, Molecular biology and Bioinformatics.
Omixon has approximately 58 employees.
Omixon has completed 4 funding rounds. The latest funding stage is Series C.
Top alternatives and competitors to Omixon include CareDx, Inc., GeneCast Biotechnology Co., Ltd., BMR Genomics, Dyno Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Omixon and CareDx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Omixon, https://bouncewatch.com/company/omixon, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout